The Breast Cancer Clinical Research Unit (BCCRU) focuses on the translational interface of therapeutic development. Breast cancer is a heterogeneous disease, and thus, there are large inter-patient variations in terms of disease course, prognosis, relapse and resistance to conventional or targeted therapeutics. Our activities are directed towards personalised treatment, and range from preclinical models to the sponsoring of multicentric clinical trials. Specifically, our research areas are:
Discovery of new targets for breast cancer prevention.
Breast cancer functional taxonomy: by using a systems biology approach, we are clustering the disease into subtypes defined by biologic features that constitute therapeutic targets.
Study of the mechanisms of resistance against targeted therapies.
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. (2017).Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.. Oncogene 36, 2737-2749. Publicación CNIO.
Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA (2017).Critically short telomeres and toxicity of chemotherapy in early breast cancer. Oncotarget 8, 21472-21842. Publicación CNIO.
Mateo F, Arenas E, Aguilar H, Serra-Musach J, Ruiz de Garibay G, Boni J, Maicas M, Du S, Iorio F, Herranz C, Isam A, Prado X, Llorente A, Petit A, Vidal A, Catala I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts A, Weerd V, Look MP, Puertas S, GArcia N, Perkins AS, Bonifaci N, Skowron M, Gomez-Baldo L, Hernandez V, Martinez A, Martinez-Iniesta M, Serrat X, Ceron J, Brunet J, Barretina MP, Gil M, Falo C, Fernandez A, Morilla I, Pernas S, Pla MJ, Andreu X, Seguí MA, Ballester R, Castellá E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Sanchez-Mut JV, Gonzalez-Suarez E, Cordero A, Sanchez Cespedes M, Gajewski TF,Cohen EEZ, Jesiotr M, Bodnar L, Quintela-Fandino M, Lopez-Bigas N, Viñals F, Casanovas O, Graupera M, Hernandez-Losa J, Ramon y Cajal S, Saez-Rodriguez J, Esteller M, Sierra A, Martin-Martin N, Matheu A, Carracedo A, Nanjundan M, Cortes J, Odero M, Lazaro C, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA (2016).Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.. Oncogene (in press). Publicación CNIO.
Open Access